The role of glatiramer acetate in the early treatment of multiple sclerosis

References

• KasperLHShoemakerJMultiple sclerosis immunology: the healthy immune system vs the MS immune systemNeurology201074Suppl 1S2S820038759
   PubMed Web of Science ®Google Scholar
• FrischerJMBramowSDal-BiancoAThe relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain20091321175118919339255
   PubMed Web of Science ®Google Scholar
• De JagerPLChibnikLBCuiJSteering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 studyHavrdovaEPohlCHorakovaDAscherioAHaflerDAKarlsonEWIntegration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk scoreLancet Neurol200981111111919879194
   PubMed Web of Science ®Google Scholar
• BagertBAEpstein-Barr virus in multiple sclerosisCurr Neurol Neurosci Rep2009940541019664371
   PubMed Web of Science ®Google Scholar
• GrantWBLatitude and multiple sclerosis prevalence: vitamin D reduces risk of Epstein-Barr virus infectionMult Scler20101637320028708
   PubMed Web of Science ®Google Scholar
• CorrealeJYsrraelitMCGaitanMIImmunomodulatory effects of vitamin D in multiple sclerosisBrain20091321146116019321461
   PubMed Web of Science ®Google Scholar
• KampmanMTBrustadMVitamin D: a candidate for the environmental effect in multiple sclerosis-observations from NorwayNeuroepidemiology20083014014618382112
   PubMed Web of Science ®Google Scholar
• SimonKCMungerKLPolymorphisms in vitamin D metabolism related genes and risk of multiple sclerosisMult Scler20101613313820007432
   PubMed Web of Science ®Google Scholar
• Dhib-JalbutSMarksSInterferon-beta mechanisms of action in multiple sclerosisNeurology201074Suppl 1S17S2420038758
   PubMed Web of Science ®Google Scholar
• RackeMKLovett-RackeAEKarandikarNJThe mechanism of action of glatiramer acetate treatment in multiple sclerosisNeurology20105;74Suppl 1S25S3020038760
   PubMed Web of Science ®Google Scholar
• ZiemssenTSchrempfWGlatiramer acetate: mechanisms of action in multiple sclerosisInt Rev Neurobiol200779527570
   Web of Science ®Google Scholar
• WeberMSHohlfeldRZamvilSMechanism of action of glatiramer acetate in treatment of multiple sclerosisJ Am Soc Exptl NeuroTherapeutics20074647653
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHCHAMPS study group. Intramuscular interferon beta-1a therapy initiated during an initial demyelinating event in multiple sclerosisN Eng J Med2000343898904
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSEdanGHartungHPMillerDHTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromeNeurology2006671242124916914693
   PubMed Web of Science ®Google Scholar
• ComiGMartinelliVRodegherMPreCISe study groupEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet20093741503151119815268
   PubMed Web of Science ®Google Scholar
• BrandesDWCallenderTLathiEO’LearySA review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse eventsCurr Med Res Opin200925779219210141
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis, the Rebif versus glatiramer acetate in relapsing MS Disease (REGARD) study), a multi-centre randomized, parallel, open label trialLancet Neurol2008790391418789766
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonBComiG250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol2009888989719729344
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPIndependent Comparison of Interferon (INCOMIN) Trial Study GroupEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• DurelliLBarberoPClericoMINCOMIN Trial Study GroupA randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisNeurology2006661056106016510769
   PubMed Web of Science ®Google Scholar
• SchwidSRPanitchHSFull results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosisClin Ther2007292031204818035202
   PubMed Web of Science ®Google Scholar
• TraboulseeAAl-SabbaghABennettRChangPLiDKEVIDENCE Study Group; UBC MS/MRI Research GroupReduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) studyBMC Neurol200881118426595
   PubMed Web of Science ®Google Scholar
• LimmrothVMalessaRZettlUKQUASIMS Study GroupQuality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosisJ Neurol2007254677717273808
   PubMed Web of Science ®Google Scholar
• ClanetMRadueEWKapposLEuropean IFNbeta-1a (Avonex) dose-comparison study investigators, a randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MSNeurology2002591507151712451189
   PubMed Web of Science ®Google Scholar
• CohenJARovarisMGoodmanAD9006 Study groupRandomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting multiple sclerosisNeurology20076893994417372130
   PubMed Web of Science ®Google Scholar
• ZivadinovRRederATFilippiMMechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisNeurology20087113614418606968
   PubMed Web of Science ®Google Scholar
• YongVWProspects of repair in multiple sclerosisJ Neurol Sci2009277Suppl 1S16S1819200859
   PubMed Web of Science ®Google Scholar
• Teva, Press Release, May 4, 2010.
   Google Scholar
• van der VoortLFGilliFBertolottoAClinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosisArch Neurol201028 [Epub ahead of print]
   Google Scholar
• FreedmanMSCohenBDhib-JalbutSRecognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandCurr Med Res Opin2009102459247019678753
   PubMed Web of Science ®Google Scholar
• RíoJComabellaMMontalbanXPredicting responders to therapies for multiple sclerosisNat Rev Neurol2009555356019794514
   PubMed Web of Science ®Google Scholar
• RudickRAPolmanCHCurrent approaches to the identification and management of breakthrough disease in patients with multiple sclerosisLancet Neurol2009854555919446274
   PubMed Web of Science ®Google Scholar
• GoodinDSDisease-modifying therapy in multiple sclerosis: update and clinical implicationsNeurology20087124 Suppl 3S8S1319064873
   PubMed Web of Science ®Google Scholar
• FoleyJBrandesDWRedefining functionality and treatment efficacy in multiple sclerosisNeurology200972S1S1119506262
   PubMed Web of Science ®Google Scholar
• CoylePKFoleyJFFoxEJJefferyDBMunschauerFEIIITornatoreCBest practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapyMult Scler200915S4S26S36
   Web of Science ®Google Scholar
• PerumalJFilippiMFordCGlatiramer acetate therapy for multiple sclerosis: a reviewExpert Opin Drug Metab Toxicol200621019102917125414
   PubMed Web of Science ®Google Scholar